cyrilzakka/clinical-trials huggingface dataset:
Effects of Multimodal Physical Therapy With and Without McConnell Taping in Patients With Anterior Knee Pain.

This study aims to determine the effect Multimodal physical therapy with and without McConnell taping on pain, functional limitation and severity of symptoms in patients with anterior knee pain.

The term "Anterior Knee Pain" is often used interchangeably with "Patellelofemoral Pain Syndrome" (PFPS or " runner's knee" which involves stiffness and pain when patellofemoral joint is loaded with different activities that require prolonged knee flexion, stairs climbing or descending , running, kneeling and squatting. Multimodal therapy and tapping techniques are useful for reducing pain and improving functional activities of patient daily living.

In this randomized clinical trial, Thirty participants with anterior knee pain will be randomly assigned to one of the two intervention groups: Group A: Group A will be treated with multimodal physical therapy program with McConnell taping. Group B: Group B will be treated with multimodal physical therapy program without McConnell taping. Randomization will be performed using a convenient random sampling method via lottery method. Each participant will receive a total of 12 treatment sessions.

over a four-week period. The effects of the interventions will be assessed at the beginning (first session), conclusion (eight session). Participants will be followed up after 4 weeks again. Outcome measures, including pain intensity, functional limitation and severity of symptoms will be evaluating using the Visual Analog Scale (VAS), Lower Extremity Functional Scale (LEFS) and Anterior Knee Pain Scale (AKPS) respectively. Data will be analyzed using SPSS software version 25. Normality of data will be assessed using the Shapiro-wilk test. For within-group comparisons, paired t- test will be used. To compare changes between the groups, the independent t-test will be applied, depending on the data distribution. The analysis of these outcome measures will provide. valuable insights into the impact of the interventions on participants' pain, functional limitation and severity of symptoms.

Eligibility Criteria:
Inclusion Criteria:

* Age 17-35 years, both male and female.
* Unilateral or bilateral pain lasting for more than 2-3 months.
* Diagnosed with patellofemoral pain by orthopedic surgeon through clinical and radiological findings.
* Positive patellofemoral grinding test, negative McCurry test and full knee range of motion.
* Pain grade 3-6 by Visual Analogue Scale (VAS).
* Pain at least in two of these positions: sitting for long time with knee bends, going up and down the stairs, squatting and running, kneeling.

Exclusion Criteria:

* History of ligament sprain, meniscal injury, knee fracture, patellar dislocation and knee osteoarthritis.
* True knee joint locking or giving away and tibial or iliotibial track tendinopathy.

Pregnancy.

* Developmental dysplasia of hip and undergoing any medical treatment.
* Spinal surgery and neurological disorders.
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.

PRIMARY OBJECTIVES:

I. To estimate the rate of platelet engraftment by day 60 in patients undergoing cord blood transplant (CBT) or haploidentical donor stem cell transplantation treated with eltrombopag (eltrombopag olamine).

SECONDARY OBJECTIVES:

I. To assess safety of eltrombopag in this population. II. To assess neutrophil engraftment with eltrombopag in this population. III. To characterize immune reconstitution. IV. To assess overall survival (OS). V. To assess progression free survival (PFS). VI. To assess incidence of acute graft-versus-host disease (GVHD).

OUTLINE: Patients are assigned to 1 of 2 arms.

ARM I (CORD BLOOD TRANSPLANT): Patients receive eltrombopag olamine orally (PO) once daily (QD) for 60 days beginning on day -1.

ARM II (HAPLOIDENTICAL DONOR STEM CELL TRANSPLANT): Patients receive eltrombopag olamine PO QD for 60 days beginning on day 5.

After completion of study treatment, patients are followed up at 1, 2, 3, 6, and 12 months.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing a cord blood or haploidentical transplantation on any protocol or standard of care treatment plan.
* Age \>/= 18.
* Females of child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding must be willing to use an effective contraceptive measure until 30 days after the last dose of eltrombopag. Males who have had sexual contact with female of child-bearing potential must be willing to use contraceptive techniques until 30 days after the last dose of eltrombopag.
* Patient or patient's legal representative(s) is/are able to provide written informed consent to participate.

Exclusion Criteria:

* ALT and AST \>/= 2.5 ULN.
* Serum direct bilirubin \>/= 1 mg/dl (except Gilbert's syndrome or hemolysis).
* Patients of east Asian ancestry (Chinese, Japanese, or Korean Origin).
* Calculated creatinine clearance \< 30ml./min. Creatinine clearance will be calculated using the MDRD method.
* Arterial or venous thrombosis in the last year except for line-related venous thrombosis more than 3 months ago.
* Positive beta HCG within 7 days prior to consent in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or breast-feeding.
Primary Prophylaxis of Gastric Varix Bleed

In patients who have never bled from gastric varix (GOV2 and IGV1), cyanoacrylate injection will be better than both beta-blocker therapy and no treatment in prevention of gastric variceal bleed. The investigators conducted a randomized controlled trial in patients with gastric varix (GOV2 and IGV1) who never bled before, to study the efficacy of treatment with cyanoacrylate injection versus beta-blocker versus no treatment in prevention of first bleed from gastric varices.

Patients are followed up every 3 months or at the time of end point or complications.

Eligibility Criteria:
Inclusion Criteria:

* Patients with GOV2 with eradicated esophageal varix or IGV1, who had never bled from gastric varix were included.

Exclusion Criteria:

* Only esophageal varix, GOV1 with GOV2, acute bleed or past history of bleed from gastric varix, contraindications to beta-blocker therapy and cyanoacrylate injection.
* Prior injection of cyanoacrylate or sclerotherapy or variceal ligation or transjugular intrahepatic portosystemic shunt or balloon-occluded retrograde transvenous obliteration or balloon-occluded endoscopic injection sclerotherapy of gastric varix for prevention of bleeding from GV
* Patients already on beta-blocker or nitrates
* Undetermined origin of bleeding from esophageal varix or gastric varix
* Hepatic encephalopathy grade III/IV
* Hepatorenal syndrome
* Hepatocellular carcinoma
* Presence of deep jaundice (serum bilirubin \> 10 mg/dl)
* Uremia
* Cerebrovascular accident
* Cardiorespiratory failure
* Pregnancy and patients not giving informed consent for endoscopic procedures
Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease

The purpose of this study is to investigate the effect of dual-mode non-invasive brain stimulation (NIBS) with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex compared with rTMS alone in patients with Parkinson's disease (PD) with freezing of gait (FOG).

Patients in the dual-mode group underwent five consecutive daily sessions of dual-mode NIBS with simultaneous high-frequency rTMS and tDCS, whereas patients in the rTMS group underwent high-frequency rTMS with sham tDCS. Assessments of FOG, motor, ambulatory and cognitive function were performed three times: at baseline before NIBS, immediately after NIBS, and one week after cessation of NIBS.

Eligibility Criteria:
Inclusion Criteria:

* diagnosed as Parkinson's disease (PD) with freezing of gait
* walk independently without walking devices

Exclusion Criteria:

* pre-existing and active major neurological diseases other than PD
* a previous history of seizures
* implanted metallic objects that would contraindicate rTMS
Brief Cognitive Behavioral Therapy to Enhance Benzodiazepine Deprescribing

The goal of this clinical trial is to conduct a single-arm pilot trial of a brief cognitive-behavioral therapy-enhanced benzodiazepine deprescribing intervention in 20 older adults (aged ≥55 years) prescribed chronic benzodiazepines by their primary care clinicians.

Nearly 10% of Americans aged 55 years and older fill benzodiazepine (BZD) prescriptions annually. Chronic use of BZD place older adults at an increased risk of falls, cognitive impairment, functional decline, preventable hospitalizations, and mortality.

Research study investigators will conduct a single-arm pilot trial of the intervention in 20 adults aged 55 and older currently taking chronic BZDs. The aim is to evaluate feasibility/acceptability of the refined deprescribing intervention using mixed methods. At intervention end, research study investigators will conduct surveys and qualitative interviews with participants to obtain feedback on participant experience and intervention components (e.g., acceptability, usefulness, relevance, satisfaction) as well as views on future format options. Using these data and the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework, research study investigators will further refine the intervention in preparation for larger scale testing and implementation.

Eligibility Criteria:
Inclusion Criteria:

* Prescribed chronic benzodiazepines by their primary care clinicians at a Beth Israel Deaconess Medical Center (BIDMC) Primary Care Clinic.

Exclusion Criteria:

* Primary Care Practitioner (PCP) opt out
* Severe anxiety or depression symptoms
A New Surgical Strategy to Protect the Inferior Parathyroid

The incidence of temporary hypoparathyroidism after thyroid surgery is 14%-60%, and the incidence of permanent hypoparathyroidism is 4%-11%. The protection of parathyroids has always been the focus and difficulty of thyroid surgery. The anatomical position of the superior parathyroids is relatively fixed, and can be preserved in situ easily; while the anatomical position of inferior parathyroids varies greatly between patients. It is always difficult to look for, identify, and protect them. Concepts such as thyro-thymic ligament and "thymus-vascular-inferior parathyroid plane" were raised to help identify the inferior parathyroids. We found that this surgical strategy can protect inferior parathyroids in situ effectively in our retrospective studies. Thus, we are going to carry out a prospective study to compare the new method and the traditional method of thyroidectomy, to see if more inferior parathyroids can be protected in situ through the new surgical strategy.


Eligibility Criteria:
Inclusion Criteria:

* initial thyroid surgery; thyroidectomy with/without central lymph node dissection

Exclusion Criteria:

* coexisting parathyroid disease; need lateral neck dissection; history of radio-iodine ablation treatment
PET Study of Breast Cancer Patients Using [68Ga]ABY-025

The study will evaluate \[68Ga\]ABY-025 for PET imaging of HER2 expression in subjects with HER2-positive or HER2-negative breast cancer.

Open-labeled, exploratory, single center study.

1. Group 1 (dose-finding) Six subjects with HER2-positive primary tumor status and four subjects with HER2-negative status. \[68Ga\]ABY-025 PET with low dose (100 μg) of ABY-025 peptide is performed, followed by a repeated PET within three weeks using high dose (500 μg) ABY-025 peptide (radioactivity maximum 500 MBq). A third \[68Ga\]ABY-025 PET will be performed in the HER2-positive subgroup only, when signs of progressive disease are found at routine clinical evaluation or else latest after 12 months regardless of disease status, then using the ABY-025 peptide dose previously determined to be preferable.
2. Group 2 Ten subjects with HER2-positive primary tumor status. \[68Ga\]ABY-025 PET is performed using the ABY-025 peptide dose determined to be preferable during the dose-finding part of the study, followed by a second \[68Ga\]ABY-025 PET investigation at signs of progressive disease or else latest after 9 months.

Eligibility Criteria:
Inclusion Criteria:

1. Subject is \> 18 years of age
2. Diagnosis of invasive breast cancer with metastases
3. Availability of results from HER2 status previously determined on material from the primary tumor, either

   1. HER2-positive, defined as a DAKO HercepTest™ score of 3+ or FISH positive or
   2. HER2-negative, defined as a DAKO HercepTest™ score of 0 or 1+ or else; if 2+ then FISH negative
4. Volumetrically quantifiable metastasis lesions on CT or MRI, with at least one lesion \>= 10 mm in smallest diameter and suitable for biopsy
5. ECOG performance status of =\< 2
6. Life expectancy of at least 12 weeks
7. Hematological, liver and renal function test results within the following limits:

   White blood cell count: \> 2.0 x 10\^9/L Haemoglobin: \> 80 g/L Platelets: \> 50.0 x 10\^9/L ALT, ALP, AST: =\< 5.0 times Upper Limit of Normal Bilirubin =\< 2.0 times Upper Limit of Normal Serum creatinine: Within Normal Limits or else normal clearance
8. A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all female patients of childbearing potential, who must use a medically acceptable form of contraception from study start until at least 30 days after study termination
9. Subject is able to participate in the diagnostic investigations to be performed in the study
10. Informed consent

Exclusion Criteria:

1. Manifest second, non-breast malignancy
2. Known HIV positive or chronically active hepatitis B or C
3. Administration of other investigational medicinal product within 30 days of screening
4. Ongoing toxicity \> grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's "Common Terminology Criteria for Adverse Events v4.0 \[CTCAE\]"
5. Other ongoing severe disease that may influence the patient's ability to participate in the study
6. Pregnant or breast-feeding
Activating Behavior for Lasting Engagement After Stroke

Stroke survivors demonstrate high levels of sedentary behavior, placing them at risk for exacerbation of chronic health conditions. This may lead to recurrent stroke. Subtle cognitive impairments are common after stroke and can lead to difficulty self-monitoring and problem solving to overcome barriers to physical activity. Investigators developed the Activating Behavior for Lasting Engagement (ABLE) intervention to promote activity scheduling, self-monitoring, and problem solving activity over the full day. This study examines the effects of the ABLE intervention on sedentary behavior after stroke.

The study advisory committee added a dose-matched, no-intervention delayed baseline to the study protocol following initial documentation of this study protocol on clinicaltrials.gov. The purpose of this delayed baseline design was to assess the baseline stability on the primary and secondary outcomes. The addition of this timepoint resulted in a shift of post-intervention timepoints as follows: Baseline 1 (week 1), Baseline 2 (week 6), Post-intervention (week 11), and Follow-up (week 18). Intervention was delivered between Baseline 2 and Post-intervention.

Eligibility Criteria:
Inclusion Criteria:

1. diagnosis of ischemic or hemorrhagic stroke
2. ≥6 months and ≤24 months post-stroke
3. ≥18 years of age
4. ambulatory in the community with or without an assistive device (e.g. walker, cane)
5. self-reported sedentary behavior (≥6 hours/day of sedentary behavior reported using the Sedentary Behavior Questionnaire)
6. reside within 50 miles of Pittsburgh, Pennsylvania

Exclusion Criteria:

1. severe aphasia (Boston Diagnostic Aphasia Examination score ≤1)
2. currently receiving outpatient or home care rehabilitation services (physical therapy, occupational therapy, or speech therapy)
3. current active cancer treatment
4. medical history of neurodegenerative disorder (i.e. dementia, Parkinson's disease, multiple sclerosis, Lou Gehrig's disease (ALS), glioblastoma, myasthenia gravis)
5. current major depressive disorder, psychiatric condition, substance abuse (Patient Health Questionnaire-9, PRIME-MD/MINI)
Results of the Tactys Implant in Proximal Interphalangeal Joint Arthroplasty

Study at middle term of the functional and radiographic results of proximal interphalangeal joint arthroplasty with the Tactys prothesis. The aim is to evaluate if the short term results are maintained in time.

The inclusion criteria is any patient who has undergone a proximal interphalangeal joint arthroplasty with the Tactys prothesis between january 2015 to january 2020 in the Centre Chirurgical Emile Gallé in Nancy.

The functional results evaluated are range of motion, force, pain, functional score as Quick DASH and the radiological one are clinodactyly, periprosthetic ossifications and loosening, dislocation and implant subsidence.

Data is registered from the medical folder of every patient.

Eligibility Criteria:
Inclusion Criteria:

* one or more proximal interphalangeal joint arthroplasty of long fingers with the Tactys prosthesis
* between january 2015 to january 2020
* major
* centre chirurgical emile gallé, centre hospitalier régional universitaire de Nancy

Exclusion Criteria:

* minor
Effectiveness of the Kinesio Taping® in Muscle Activation

Forty-eight female patients will be randomized into three groups to receive the Kinesio taping, placebo Kinesio taping and control group. The group Kinesio taping receive the correct application of the method described. The placebo group will receive a placement without tension. The control group did not receive any form of intervention.

The group Kinesio taping receive the correct application of the method described with tension of 40%. The placebo group will receive a placement without tension.

The control group did not receive any form of intervention.

Eligibility Criteria:
Inclusion Criteria:

* Woman
* Sedentary

Exclusion Criteria:

* Physically active,
* pain
* men
* musculoskeletal injury in the last six months.
Data Collection in Lutetium Treated Prostate Cancer: Recording of Progression and Tumor Characteristics

This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.


Eligibility Criteria:
Inclusion Criteria:

* Participants should be at least 18 years old.
* Participants should be able to understand the written information and be able to provide informed consent.
* Participants are planned to start treatment with Lu-PSMA as a part of regular clinical care.

Exclusion Criteria:

None applicable
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.


Eligibility Criteria:
Inclusion Criteria:

* Participants must have a history of migraine with or without aura as defined by International Headache Society International Classification of Headache Disorders, 3rd edition (ICHD-3) (ICHD-3 2018) diagnostic criteria 1.1 or 1.2.1 and meets the following criteria:

  * History of migraine attacks for more than 6 months
  * Reports at least 2 and no more than 8 moderate-to-severe migraine attacks per month in the 2 months prior to screening visit
  * Duration of a typical untreated migraine attack (excluding sleep) is greater than or equal to 3 hours
  * Participant has not, by history, experienced satisfactory response with a previous migraine therapy, in the opinion of the investigator
* Participant must be able to swallow a tablet
* For participants taking migraine preventive medication, treatment regimen is stable and has been taken for at least 3 months prior to screening
* Participants must weigh at least 15 kilograms (kg)

Exclusion Criteria:

* Participants must not be pregnant or nursing
* Participants must not have any acute, serious, or unstable medical condition
* Participants must not be actively suicidal or at significant risk for suicide, in the opinion of the investigator
Pain Map DK: a Prospective Cohort Study of Pain Treatment in 500 Hip Arthroplasty Patients at Different Danish Hospitals

This is a prospective observational cohorte study. The aim is to investigate actual pain treatment and outcomes in a large population of total hip arthroplasty patients at 5 different hospitals in Denmark.


Eligibility Criteria:
Inclusion Criteria:

* Primary planned total hip arthroplasty, Able to understand and speak english or danish.

Exclusion Criteria:

* patients not able to cooperate, patients with alcohol or drug abuse